Literature DB >> 20631980

Receptor for AGEs (RAGE) blockade may exert its renoprotective effects in patients with diabetic nephropathy via induction of the angiotensin II type 2 (AT2) receptor.

K C Sourris1, A L Morley, A Koitka, P Samuel, M T Coughlan, S A Penfold, M C Thomas, A Bierhaus, P P Nawroth, H Yamamoto, T J Allen, T Walther, T Hussain, M E Cooper, J M Forbes.   

Abstract

AIMS/HYPOTHESIS: The receptor for AGEs (RAGE) contributes to the development and progression of diabetic nephropathy. In this study, we examined whether the protective effects of RAGE blockade are exerted via modulation of the renal angiotensin II type 2 (AT2) receptor.
METHODS: Control and streptozotocin diabetic mice, wild-type or deficient in the AT2 receptor (At2 knockout [KO]) or RAGE (Rage KO), were studied for 24 weeks. Adenoviral overexpression of full-length Rage in primary rat mesangial cells was also used to determine the effects on AT2 production.
RESULTS: With diabetes, Rage-deficient mice had less albuminuria, and an attenuation of hyperfiltration and glomerulosclerosis as compared with diabetic wild-type and At2 KO mice. Renal gene and protein expression of RAGE was elevated with diabetes. Diabetic Rage KO mice had a greater increase in renal AT2 receptor protein than was seen in diabetic wild-type mice. Diabetes-induced increases in renal cytosolic and mitochondrial superoxide generation were prevented in diabetic Rage KO mice, but enhanced in all At2 KO mice. Adenoviral overexpression of RAGE or AGE treatment decreased cell surface AT2 expression, in association with increasing superoxide generation; both were reversed using antioxidants N-acetylcysteine and apocynin, and soluble RAGE in primary mesangial cells. CONCLUSIONS/
INTERPRETATION: RAGE appears to be a common and key modulator of AT2 receptor expression, a finding that would implicate a newly defined RAGE-AT2 axis in the development and progression of diabetic nephropathy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20631980      PMCID: PMC4926314          DOI: 10.1007/s00125-010-1837-2

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  50 in total

1.  Characterization of a novel EGFP reporter mouse to monitor Cre recombination as demonstrated by a Tie2 Cre mouse line.

Authors:  R Constien; A Forde; B Liliensiek; H J Gröne; P Nawroth; G Hämmerling; B Arnold
Journal:  Genesis       Date:  2001-05       Impact factor: 2.487

2.  RAGE control of diabetic nephropathy in a mouse model: effects of RAGE gene disruption and administration of low-molecular weight heparin.

Authors:  Khin-Mar Myint; Yasuhiko Yamamoto; Toshio Doi; Ichiro Kato; Ai Harashima; Hideto Yonekura; Takuo Watanabe; Harumichi Shinohara; Masayoshi Takeuchi; Koichi Tsuneyama; Noriyoshi Hashimoto; Masahide Asano; Shin Takasawa; Hiroshi Okamoto; Hiroshi Yamamoto
Journal:  Diabetes       Date:  2006-09       Impact factor: 9.461

3.  Role of AT2 receptor in the brain in regulation of blood pressure and water intake.

Authors:  Zhen Li; Masaru Iwai; Lan Wu; Tetsuya Shiuchi; Toyohisa Jinno; Tai-Xing Cui; Masatsugu Horiuchi
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-09-05       Impact factor: 4.733

4.  Sustained hypersensitivity to angiotensin II and its mechanism in mice lacking the subtype-2 (AT2) angiotensin receptor.

Authors:  H M Siragy; T Inagami; T Ichiki; R M Carey
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-25       Impact factor: 11.205

5.  Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study.

Authors:  C E Mogensen; S Neldam; I Tikkanen; S Oren; R Viskoper; R W Watts; M E Cooper
Journal:  BMJ       Date:  2000-12-09

6.  Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE.

Authors:  M P Wautier; O Chappey; S Corda; D M Stern; A M Schmidt; J L Wautier
Journal:  Am J Physiol Endocrinol Metab       Date:  2001-05       Impact factor: 4.310

7.  Utility of endogenous creatinine clearance as a measure of renal function in mice.

Authors:  Stephen R Dunn; Zhonghua Qi; Erwin P Bottinger; Matthew D Breyer; Kumar Sharma
Journal:  Kidney Int       Date:  2004-05       Impact factor: 10.612

8.  Angiotensin II upregulates RAGE expression on podocytes: role of AT2 receptors.

Authors:  Christiane Rüster; Tzvetanka Bondeva; Sybille Franke; Nobushige Tanaka; Hiroshi Yamamoto; Gunter Wolf
Journal:  Am J Nephrol       Date:  2009-01-08       Impact factor: 3.754

9.  Prophylactic and therapeutic treatments with AT 1 and AT 2 receptor antagonists and their effects on changes in the severity of pancreatitis.

Authors:  Siu Wai Tsang; Siu Po Ip; Po Sing Leung
Journal:  Int J Biochem Cell Biol       Date:  2004-02       Impact factor: 5.085

10.  c-Jun NH2-terminal kinase activity in subcutaneous adipose tissue but not nuclear factor-kappaB activity in peripheral blood mononuclear cells is an independent determinant of insulin resistance in healthy individuals.

Authors:  Karly C Sourris; Jasmine G Lyons; Maximilian P J de Courten; Sonia L Dougherty; Darren C Henstridge; Mark E Cooper; Michelle Hage; Anthony Dart; Bronwyn A Kingwell; Josephine M Forbes; Barbora de Courten
Journal:  Diabetes       Date:  2009-03-03       Impact factor: 9.461

View more
  29 in total

Review 1.  The pathobiology of diabetic vascular complications--cardiovascular and kidney disease.

Authors:  Stephen P Gray; Karin Jandeleit-Dahm
Journal:  J Mol Med (Berl)       Date:  2014-04-01       Impact factor: 4.599

2.  Deletion of bone-marrow-derived receptor for AGEs (RAGE) improves renal function in an experimental mouse model of diabetes.

Authors:  Greg Tesch; Karly C Sourris; Shaun A Summers; Domenica McCarthy; Micheal S Ward; Danielle J Borg; Linda A Gallo; Amelia K Fotheringham; Allison R Pettit; Felicia Y T Yap; Brooke E Harcourt; Adeline L Y Tan; Joshua Y Kausman; David Nikolic-Paterson; Arthur R Kitching; Josephine M Forbes
Journal:  Diabetologia       Date:  2014-06-24       Impact factor: 10.122

3.  Deletion of the formin Diaph1 protects from structural and functional abnormalities in the murine diabetic kidney.

Authors:  Michaele B Manigrasso; Richard A Friedman; Ravichandran Ramasamy; Vivette D'Agati; Ann Marie Schmidt
Journal:  Am J Physiol Renal Physiol       Date:  2018-08-22

Review 4.  AGE restriction in diabetes mellitus: a paradigm shift.

Authors:  Helen Vlassara; Gary E Striker
Journal:  Nat Rev Endocrinol       Date:  2011-05-24       Impact factor: 43.330

5.  Advanced Glycation End Products Stimulate Angiotensinogen Production in Renal Proximal Tubular Cells.

Authors:  Joseph M Garagliano; Akemi Katsurada; Kayoko Miyata; Andrei V Derbenev; Andrea Zsombok; L Gabriel Navar; Ryousuke Satou
Journal:  Am J Med Sci       Date:  2018-10-24       Impact factor: 2.378

6.  Vascular remodeling and arterial calcification are directly mediated by S100A12 (EN-RAGE) in chronic kidney disease.

Authors:  Joseph Gawdzik; Liby Mathew; Gene Kim; Tipu S Puri; Marion A Hofmann Bowman
Journal:  Am J Nephrol       Date:  2011-03-02       Impact factor: 3.754

7.  Diminazene aceturate prevents nephropathy by increasing glomerular ACE2 and AT2 receptor expression in a rat model of type1 diabetes.

Authors:  Santosh Kumar Goru; Almesh Kadakol; Vajir Malek; Anuradha Pandey; Nisha Sharma; Anil Bhanudas Gaikwad
Journal:  Br J Pharmacol       Date:  2017-08-11       Impact factor: 8.739

8.  Targeting of receptor for advanced glycation end products suppresses cyst growth in polycystic kidney disease.

Authors:  Eun Young Park; Bo Hye Kim; Eun Ji Lee; EunSun Chang; Dae Won Kim; Soo Young Choi; Jong Hoon Park
Journal:  J Biol Chem       Date:  2014-02-10       Impact factor: 5.157

Review 9.  Pathophysiology of the diabetic kidney.

Authors:  Volker Vallon; Radko Komers
Journal:  Compr Physiol       Date:  2011-07       Impact factor: 9.090

10.  Inhibitors of Advanced Glycation End Product (AGE) Formation and Accumulation.

Authors:  Karly C Sourris; Anna Watson; Karin Jandeleit-Dahm
Journal:  Handb Exp Pharmacol       Date:  2021
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.